Skip to main content
Back
LLY logo

Eli Lilly and Company

Data quality: 100%
LLY
NYSE Healthcare Drug Manufacturers - General
$902.53
▼ $8.02 (-0.88%)
Mkt Cap: 852.73B
Day Range
$895.61 $908.67
52-Week Range
$623.78 $1,133.95
Volume
1,728,145
50D / 200D Avg
$1,024.73 / $892.56
Prev Close
$910.55

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 41.3 0.3
P/B 32.1 2.9
ROE % 101.4 3.7
Net Margin % 31.7 3.8
Rev Growth 5Y % 23.2 10.0
D/E 1.6 0.2

Analyst Price Target

Hold
$1,243.95 +37.8%
Low: $985.00 High: $1,350.00
Forward P/E
26.5
Forward EPS
$34.43
EPS Growth (est.)
+0.0%
Est. Revenue
82 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $60.97
$56.29 – $66.45
 130 B 3
FY2029 $55.40
$51.14 – $60.38
 120 B 3
FY2028 $49.21
$42.81 – $55.86
 110 B 9

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Mar 16, 2026
Fyrwald J Erik
Director
 grant 10 $989.12 $9,891
Feb 17, 2026
Sulzberger Gabrielle
Director
 grant 5 $1,036.05 $5,180
Feb 16, 2026
Brown Adrienne S
EVP, President LLY Imm
 other 952 — —
Feb 9, 2026
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
 grant 4,163 $1,044.67 $4,348,961
Feb 9, 2026
Jonsson Patrik
EVP & President, LLY Int'l
 grant 4,818 $1,044.67 $5,033,220
Feb 9, 2026
Brown Adrienne S
EVP, President LLY Imm
 grant 1,196 $1,044.67 $1,249,425
Feb 9, 2026
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
 grant 4,866 $1,044.67 $5,083,364
Feb 9, 2026
Montarce Lucas
EVP & CFO
 grant 1,365 $1,044.67 $1,425,975
Feb 9, 2026
Ricks David A
President, Chair, and CEO
 grant 38,914 $1,044.67 $40,652,288
Feb 1, 2026
Jonsson Patrik
EVP & President, LLY Int'l
 other 9,612 — —
Feb 1, 2026
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
 other 10,125 — —
Feb 1, 2026
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
 other 8,300 — —
Jan 20, 2026
Sulzberger Gabrielle
Director
 grant 5 $1,041.29 $5,206
Dec 15, 2025
Fyrwald J Erik
Director
 grant 9 $1,062.19 $9,560
Dec 15, 2025
LUCIANO JUAN R
Director
 grant 14 $1,062.19 $14,871
Nov 17, 2025
Kaelin William G Jr
Director
 grant 215 $1,021.70 $219,666
Oct 20, 2025
Fyrwald J Erik
Director
 grant 12 $808.96 $9,708
Sep 15, 2025
LUCIANO JUAN R
Director
 grant 20 $748.19 $14,964
Aug 12, 2025
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
 buy 1,000 $634.41 $634,405
Aug 12, 2025
Sulzberger Gabrielle
Director
 buy 117 $641.18 $75,018

Key Takeaways

Revenue grew 23.17% annually over 5 years — strong growth
Earnings grew 94.88% over the past year
ROE of 101.35% indicates high profitability
Net margin of 31.66% shows strong profitability
Generating 8.97B in free cash flow
P/E of 41.32 — premium valuation

Growth

Revenue Growth (5Y)
23.17%
Revenue (1Y)44.70%
Earnings (1Y)94.88%
FCF Growth (3Y)N/A

Quality

Return on Equity
101.35%
ROIC32.26%
Net Margin31.66%
Op. Margin45.56%

Safety

Debt / Equity
1.60
Current Ratio1.58
Interest Coverage37.34

Valuation

P/E Ratio
41.32
P/B Ratio32.14
EV/EBITDA29.91
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 44.70% Revenue Growth (3Y) 38.20%
Earnings Growth (1Y) 94.88% Earnings Growth (3Y) 98.45%
Revenue Growth (5Y) 23.17% Earnings Growth (5Y) 38.67%
Profitability
Revenue (TTM) 65.18B Net Income (TTM) 20.64B
ROE 101.35% ROA 18.35%
Gross Margin 83.79% Operating Margin 45.56%
Net Margin 31.66% Free Cash Flow (TTM) 8.97B
ROIC 32.26% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.60 Current Ratio 1.58
Interest Coverage 37.34 Dividend Yield 0.01%
Valuation
P/E Ratio 41.32 P/B Ratio 32.14
P/S Ratio 13.08 PEG Ratio 0.49
EV/EBITDA 29.91 Dividend Yield 0.01%
Market Cap 852.73B Enterprise Value 888.07B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 65.18B 45.04B 34.12B 28.54B 28.32B
Net Income 20.64B 10.59B 5.24B 6.24B 5.58B
EPS (Diluted) 22.95 11.71 5.80 6.57 5.85
Gross Profit 54.62B 36.62B 27.04B 21.91B 21.01B
Operating Income 29.70B 17.50B 10.79B 8.65B 7.93B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112.48B 78.71B 64.01B 49.49B 48.81B
Total Liabilities 85.94B 64.44B 53.14B 38.71B 39.65B
Shareholders' Equity 26.54B 14.19B 10.77B 10.65B 8.98B
Total Debt 42.50B 33.64B 25.23B 16.24B 16.88B
Cash & Equivalents 7.16B 3.27B 2.82B 2.07B 3.82B
Current Assets 55.63B 32.74B 25.73B 18.03B 18.45B
Current Liabilities 35.23B 28.38B 27.29B 17.14B 15.05B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Growth Investing (Philip Fisher)
#13 of 157
89
Custom Full Throttle
#44 of 146
54

Recent Activity

Entered Growth Investing (Philip Fisher)
Mar 24, 2026
Entered Full Throttle
Mar 24, 2026